Atlas Trials

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Clinical trial NCT04767594 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04767594
Sponsor
Pfizer
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Breast Neoplasms
Start date
2020-10-27
Primary completion
2028-04-03
Enrollment
1407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.